A
AtaCor Medical
Designing innovative solutions for cardiac rhythm management, including the AtaCor EV Temporary Pacing Lead System
About AtaCor Medical
AtaCor Medical is a pioneering company in the field of cardiac rhythm management, dedicated to advancing the standard of care through innovative temporary pacing solutions. The company operates in the medical device market, focusing on developing extravascular pacing systems that do not require entry into the heart, vascular system, or cath lab. This approach aims to eliminate the complications associated with traditional transvenous leads and improve patient comfort by avoiding transcutaneous pacing.
AtaCor Medical's primary product, the AtaCor EV Temporary Pacing System, is designed to deliver reliable and prompt temporary pacing without the need for imaging, allowing for safe post-procedure ambulation. Additionally, the company is developing the AtaCor EV ICD Lead System, which leverages anatomical landmarks for extravascular lead delivery and is compatible with DF-4 technology. This system aims to provide the convenience, cost savings, and therapeutic benefits of traditional TV ICDs without the associated complications.
The company's business model revolves around the development and eventual commercialization of these innovative medical devices, targeting healthcare providers and institutions that specialize in cardiac care. Revenue generation is expected through the sale of these devices once they receive regulatory approval for commercial use.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 90.6/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- medical implants, Surgery, Cardiology and cardiovascular, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2024 | $28M | $112M | BayMed Venture Partners · Arboretum Ventures · Hatteras Venture Partners · Catalyst Health Ventures | ↗ |
| SERIES BOther financing | Apr 2020 | $25M | $100M | Catalyst Health Ventures · aMoon Fund · Longview Ventures · Hatteras Venture Partners | ↗ |
Growth signals
Latest recorded traffic for AtaCor Medical is 110 monthly website visits, down 89% over the last three months. AtaCor Medical's team grew 32% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
AtaCor Medical in the San Clemente ecosystem
The AtaCor Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Broadview Ventures
aMoon Fund- CVCatalyst Health Ventures
Longview Ventures
Hatteras Venture Partners
Series B and later2 investors entered at this stage
Arboretum Ventures
BayMed Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AtaCor Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AtaCor Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.





